Other languages Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
0.895 ^USD	-0.56%		+1.64%	-31.15%

03-26	Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-19	Sector Update: Health Care Stocks Rise Late Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Sector Update: Health Care Stocks Rise Late Afternoon	03-19
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	03-19
Enveric Biosciences Signs Licensing Term Sheets for Joint Disease Treatment Compounds; Shares Rise	03-19
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	03-19
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	03-19
Enveric Biosciences Issues 228,690 Shares in Direct Offering	03-11
Top Midday Gainers	02-29
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	02-29
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	02-29
Sector Update: Health Care Stocks Rise in Late Afternoon	02-23
Sector Update: Health Care Stocks Advance Friday Afternoon	02-23
Enveric Biosciences Surging on Plans to Sell Cannabinoid IP Portfolio, Focus Shift to Psilocin Therapies	02-23
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	02-21
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	01-03
Enveric Bioscience Generates $1.8 Million as Investors Exercise Warrants	12-29
Sector Update: Health Care Stocks Rise in Late Afternoon	12-28
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	12-28
Enveric Biosciences Selects EB-003 as Lead Drug Candidate to Treat Mental Health Disorders	12-28
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	12-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Other languages

Filters